News
DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...
Most Britons could soon use weight loss jabs to live longer, Britain’s most eminent medic has said. Experts hailed a “golden age” in obesity treatment thanks to drugs which have been found to halve ...
The NHS has been urged to accelerate the rollout of weight loss drugs to “many millions” of people, as experts hailed the start of a “golden age” of anti-obesity treatments. A raft of studies ...
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...
Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...
A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...
Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...
New study finds weight loss jabs not only help tackle obesity but may significantly reduce alcohol use, offering wide health ...
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results